Protara Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Protara Therapeutics, Inc. Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases. The company advances its lead investigational cell therapy TARA-002, derived from the OK-432 immunopotentiator approved in Japan and Taiwan as Picibanil for oncologic indications and lymphatic malformations, in Phase 2 open-label trials for non-muscle invasive bladder cancer with high-grade carcinoma in situ in BCG-unresponsive and BCG-naive patients, as well as for macrocystic and mixed cystic lymphatic malformations in pediatric patients, which has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration and orphan drug designation from the European Commission; it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy with Orphan Drug and Fast Track Designations for preventing choline deficiency in patients on long-term parenteral nutrition or support where oral or enteral routes are inadequate. Protara Therapeutics, Inc. operates primarily in the United States, targeting patients with significant unmet needs in oncology and rare pediatric conditions. Founded in 2017 and headquartered at 345 Park Avenue South, 3rd Floor, New York, NY, the company completed an oversubscribed $45 million private placement in April 2024 led by institutional investors including RA Capital Management and Acorn Bioventures to fund clinical trials such as the ADVANCED-2 Phase 2 study expansion for TARA-002 in bladder cancer, manufacturing, and operations into 2026, and reported positive interim Phase 2 data for TARA-002 in BCG-unresponsive bladder cancer in December 2024 with STARBORN-1 trial results for lymphatic malformations on track for the fourth quarter of 2025.
Company News
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
What Makes Protara Therapeutics (TARA) a New Buy Stock
ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS
Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Increase in Short Interest
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer